CRISPR Takes the Front Seat in CART-Cell Development Claudia Manriquez-RomanElizabeth L. SieglerSaad S. Kenderian Leading Article 27 February 2021 Pages: 113 - 124
Immunogenicity Challenges Associated with Subcutaneous Delivery of Therapeutic Proteins Nicole L. JarviSathy V. Balu-Iyer Review Article 01 February 2021 Pages: 125 - 146
Recent Achievements and Challenges in Prolonging the Serum Half-Lives of Therapeutic IgG Antibodies Through Fc Engineering Sanghwan KoMigyeong JoSang Taek Jung Review Article 19 February 2021 Pages: 147 - 157
Clinical Development of New Antibody–Drug Conjugates in Breast Cancer: To Infinity and Beyond Romualdo Barroso-SousaSara M. Tolaney Review Article 05 March 2021 Pages: 159 - 174
Biologics and Targeted Synthetic Drugs Can Induce Immune-Mediated Glomerular Disorders in Patients with Rheumatic Diseases: An Updated Systematic Literature Review Elisabetta ChessaMatteo PigaAlberto Cauli Systematic Review Open access 17 February 2021 Pages: 175 - 186
Maintaining Clinical Freedom Whilst Achieving Value in Biologics Prescribing: An Integrated Cross-Specialty Consensus of UK Dermatologists, Rheumatologists and Gastroenterologists Tim RaineMaria Angeliki GkiniAmy C. Foulkes Original Research Article Open access 26 February 2021 Pages: 187 - 199
Safety of Intravitreal Gene Therapy for Treatment of Subjects with Leber Hereditary Optic Neuropathy due to Mutations in the Mitochondrial ND4 Gene: The REVEAL Study Catherine Vignal-ClermontJean-François GirmensJosé-Alain Sahel Original Research Article Open access 10 February 2021 Pages: 201 - 214
New Insight on the Safety of Erenumab: An Analysis of Spontaneous Reports of Adverse Events Recorded in the US Food and Drug Administration Adverse Event Reporting System Database Maurizio SessaMorten Andersen Original Research Article 20 February 2021 Pages: 215 - 227
Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS) Andrew BlauveltCraig L. LeonardiPiotr Wiland Original Research Article Open access 02 March 2021 Pages: 229 - 238
Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database Kaniz Afroz TanniCong Bang TruongJingjing Qian Original Research Article 13 January 2021 Pages: 239 - 254
